New clinical data confirms Castle Biosciences' TissueCypher platform provides critical risk stratification for Barrett's esophagus patients, potentially accelerating clinical adoption.
Castle Biosciences' TissueCypher platform is gaining clinical validation as studies presented at ACG 2026 demonstrate its ability to identify patients with Barrett's esophagus who are at an elevated risk of progression. By providing molecular risk assessment that transcends traditional biopsy findings, the test offers actionable insights that improve surveillance and treatment decision-making, which is expected to drive broader physician adoption and market penetration.
It provides molecular risk assessment that helps clinicians identify patients with Barrett's esophagus who are at an elevated risk of progression, informing better surveillance and treatment decisions.
Unlike traditional biopsy findings alone, TissueCypher offers molecular-level insights that assist in risk stratification beyond standard histopathology.
Castle Biosciences released new clinical data demonstrating that its TissueCypher molecular risk assessment tool effectively identifies patients with Barrett's esophagus at elevated risk of progression. These findings underscore the diagnostic utility of the platform in guiding surveillance and treatment decisions beyond traditional biopsy methods.
The data demonstrates that TissueCypher can accurately identify patients with Barrett's esophagus who are at an elevated risk of disease progression, allowing for more informed surveillance and treatment planning.